Stockscreener 앱 받기
11.82
2.64%
-0.32
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales - Yahoo Finance UK
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD - Finviz
Voya Investment Management LLC Trims Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix Earnings Notes - Trefis
Assenagon Asset Management S.A. Sells 148,100 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Trading Systems Reacting to (OCUL) Volatility - Stock Traders Daily
Revenue per share of Ocular Therapeutix Inc – BER:0OT - TradingView — Track All Markets
Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt? - 富途牛牛
Aug Action: Is Ocular Therapeutix Inc. (0OT) stock among top earnings playsMarket Sentiment Report & High Yield Stock Recommendations - Улправда
What is the fair value of Ocular Therapeutix Inc. stock nowTrade Volume Report & Long Hold Capital Preservation Plans - ulpravda.ru
Can Ocular Therapeutix Inc. stock hit analyst price targetsMarket Performance Recap & Capital Protection Trade Alerts - ulpravda.ru
Is Ocular Therapeutix Inc. (0OT) stock worth buying before Fed action2025 Top Gainers & Verified Short-Term Plans - ulpravda.ru
Is Ocular Therapeutix Inc. (0OT) stock among top earnings playsMarket Trend Summary & Reliable Breakout Forecasts - Улправда
Volume Summary: What is the fair value of Ocular Therapeutix Inc. stock now - ulpravda.ru
Can Ocular Therapeutix Inc. (0OT) stock retain market dominanceEarnings Recap Summary & Weekly Stock Performance Updates - DonanımHaber
How Ocular Therapeutix Inc. stock reacts to job market dataWeekly Trading Summary & Real-Time Buy Signal Alerts - DonanımHaber
What makes Ocular Therapeutix Inc. stock attractive to growth funds2025 Market WrapUp & Real-Time Market Sentiment Reports - DonanımHaber
Why analysts raise outlook for Ocular Therapeutix Inc. (0OT) stock2025 Pullback Review & Community Trade Idea Sharing Platform - Улправда
Is Ocular Therapeutix Inc. stock in correction or buying zoneQuarterly Profit Report & Smart Swing Trading Alerts - Улправда
How Ocular Therapeutix Inc. stock benefits from global expansion2025 Fundamental Recap & Community Verified Trade Alerts - Улправда
Will Ocular Therapeutix Inc. stock reach all time highs in 2025Trade Risk Assessment & Stepwise Swing Trade Plans - ulpravda.ru
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Down 4.3%What's Next? - MarketBeat
Ocular Therapeutix enters quiet period ahead of SOL-1 milestone - MSN
Assessing Ocular Therapeutix (OCUL) Valuation After Accelerated FDA Filing Plan for AXPAXLI in Wet AMD - Sahm
Ocular Therapeutix stock could see 45% upside if trial succeeds, TD Cowen says - Investing.com Canada
RBC Capital Adjusts Ocular Therapeutix Price Target to $24 From $17, Maintains Outperform Rating - marketscreener.com
Ocular Therapeutix prepares NDA submission for wet AMD drug - MSN
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Avoiding Lag: Real-Time Signals in (OCUL) Movement - news.stocktradersdaily.com
Ocular Therapeutix Inc. (OCUL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission - Insider Monkey
15 Best Biotech Stocks to Buy According to Wall Street Analysts - Insider Monkey
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application - Insider Monkey
EyePoint Pharmaceuticals (EYPT) Maintains Positive Outlook Amid Competitive Dynamics - GuruFocus
Is Ocular Therapeutix Inc a good long term investmentAnalyst Downgrades & Big Gains Low Investment - earlytimes.in
(OCUL) Stock Soars on Accelerated Wet AMD NDA – Price, Forecast & Risk Analysis as of December 9, 2025 - ts2.tech
Ocular Therapeutix's (OCUL) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Chardan Capital Maintains Buy Rating on OCUL with $21 Price Targ - GuruFocus
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD - Eyes On Eyecare
Ocular Therapeutix: Not So Fast On The Single-Trial Bet (Rating Downgrade) (NASDAQ:OCUL) - Seeking Alpha
Ocular Therapeutix stock price target raised to $30 by RBC on wAMD trial outlook - Investing.com Canada
Ocular Therapeutix stock hits 52-week high at 14.79 USD By Investing.com - Investing.com Canada
HC Wainwright & Co. Maintains Ocular Therapeutix (OCUL) Buy Recommendation - Nasdaq
Citizens reiterates Market Outperform rating on Ocular Therapeutix stock By Investing.com - Investing.com Canada
OCUL Stock Surge: Analysts Weigh In - StocksToTrade
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission By Investing.com - Investing.com Australia
Ocular Therapeutix stock soars after plan to accelerate AXPAXLI submission - Investing.com
Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug - Sahm
Why Is Ocular Therapeutix Stock Skyrocketing Monday?Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
Paramount Skydance, Wave Life Sciences, Ocular… - inkl
Ocular Therapeutix (NASDAQ:OCUL) Receives Buy Rating from Needham & Company LLC - MarketBeat
0.57%
자본화:
|
볼륨(24시간):